Bluejay Investor Presentation Deck

The Commercial Opportunity: A Potential $1.2 Billion Total Addressable IL-6 Testing Market in Acute Care Settings (US Annual) Potential testing revenue from IL-6 testing in long-term acute care facilities (LTACs), emergency departments (EDs), and intensive care units (ICUS) DESCRIPTION Number of patients Percentage of patients with clinician ordered IL-6 tests³ Average number of IL-6 tests ordered for each patient³ Estimated number of IL-6 tests performed Cost per test to the lab4 Total Addressable Market for IL-6 testing Testing increase expected with Bluejay's Symphony IL-6 test³ Total Addressable Market with Bluejay's Symphony IL-6 test ●●● 00 DIAGNOSTICS LTACS 400,000¹ 27.5% 3.4 0.37 M $150 $56.1 M 26.4% $70.9 M 1 Harmony Healthcare: https://harmony.solutions/understanding-care-long-term-acute-care-hospitals-101/ 2National Center for Health Statistics, National Hospital Ambulatory Medical Care Survey, 2020 3Frost & Sullivan primary research 4Bluejay pricing expectations per IL-6 test under DRG coding The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA ICUS 3,100,000² 26.5% 3.7 3.0 M $150 $453.5 M 57.7% $714.9 M Bluejay's Symphony has potential to expand use of IL-6 testing in acute care settings: increase testing volumes by 54.6% raise TAM to $1.8 B EDS 5,345,000² 23.5% 3.5 4.4 M $150 $663.2 M 54.9% $1,027.3 M Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 10

View entire presentation